Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and relaxing, especially those of you on this side of the pond, where we had an extended break. Now, though, the usual routine of meetings, deadlines, and whatnot has, of course, returned. But what can you do? The world keeps spinning, after all. So please join us as we step into the Pharmalot cafeteria and brew another cup of stimulation to cope with the day ahead. Meanwhile, here are some tidbits to help you along. Hope you have a successful day.

Clinical trials being conducted in Wuhan, China, to test a Gilead Sciences (GILD) antiviral drug as a remedy for the coronavirus are going more slowly than hoped for as the drug maker struggles to recruit qualified patients, underscoring the challenges in quickly developing drugs during outbreaks, The Wall Street Journal reports. The trials, aimed at testing more than 700 patients infected with the coronavirus, have succeeded in recruiting fewer than 200 people after 10 days.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy